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A live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2
vaccine are both effective at inducing a humoral immune response and
reducing PCV2 viremia and intrauterine infection in female swine of
breeding age
Abstract
The objective of this pilot study was to determine the efficacy of inactivated (1 or 2 dose) and live-attenuated
chimeric porcine circovirus (PCV)1-2 vaccines in sows using the PCV2-spiked semen model. Thirty-five
sows were randomly divided into 6 groups: negative and positive controls, 1 dose inactivated PCV1-2 vaccine
challenged (1-VAC-PCV2), 2 dose inactivated PCV1-2 vaccine challenged (2-VAC-PCV2), 1 dose live-
attenuated PCV1-2 vaccine unchallenged (1-LIVE-VAC), and 1 dose live-attenuated PCV1-2 vaccine
challenged (1-LIVE-VAC-PCV2). The inactivated PCV1-2 vaccine induced higher levels of PCV2-specific
antibodies in dams. All vaccination strategies provided good protection against PCV2 viremia in dams,
whereas the majority of the unvaccinated sows were viremic. Four of the 35 dams became pregnant: a negative
control, a positive control, a 2-VAC-PCV2 sow, and a 1-LIVE-VAC-PCV2 sow. The PCV2 DNA was detected
in 100%, 67%, and 29% of the fetuses obtained from the positive control, inactivated vaccinated, or live-
attenuated vaccinated dams, respectively. The PCV2 antigen in hearts was only detectable in the positive
control litter (23% of the fetuses). The PCV1-2 DNA was detected in 29% of the fetuses in the litter from the
1-LIVE-VAC-PCV2 dam. Under the conditions of this pilot study, both vaccines protected against PCV2
viremia in breeding age animals; however, vertical transmission was not prevented.
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I n t r o d u c t i o n
Porcine circovirus (PCV) is a member of the Circoviridae family 
in the genus Circovirus. It is a non-enveloped, single stranded DNA 
virus with a circular genome. The genome of PCV2 contains 2 major 
open reading frames (ORF): ORF1 encodes for a protein essential for 
viral replication, and ORF2 encodes for the capsid protein (1,2). Two 
main types of PCV have been identified: PCV type 1 (PCV1) and PCV 
type 2 (PCV2), which share approximately 83% nucleotide sequence 
identity in ORF1, but only 67% identity in ORF2 (3).
A live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2 
vaccine are both effective at inducing a humoral immune response 
and reducing PCV2 viremia and intrauterine infection in female 
swine of breeding age
Michelle Hemann, Nathan M. Beach, Xiang-Jin Meng, Chong Wang,  
Patrick G. Halbur, Tanja Opriessnig
A b s t r a c t
The objective of this pilot study was to determine the efficacy of inactivated (1 or 2 dose) and live-attenuated chimeric porcine 
circovirus (PCV)1-2 vaccines in sows using the PCV2-spiked semen model. Thirty-five sows were randomly divided into 
6 groups: negative and positive controls, 1 dose inactivated PCV1-2 vaccine challenged (1-VAC-PCV2), 2 dose inactivated 
PCV1-2 vaccine challenged (2-VAC-PCV2), 1 dose live-attenuated PCV1-2 vaccine unchallenged (1-LIVE-VAC), and 1 dose 
live-attenuated PCV1-2 vaccine challenged (1-LIVE-VAC-PCV2). The inactivated PCV1-2 vaccine induced higher levels of PCV2-
specific antibodies in dams. All vaccination strategies provided good protection against PCV2 viremia in dams, whereas the 
majority of the unvaccinated sows were viremic. Four of the 35 dams became pregnant: a negative control, a positive control, a 
2-VAC-PCV2 sow, and a 1-LIVE-VAC-PCV2 sow. The PCV2 DNA was detected in 100%, 67%, and 29% of the fetuses obtained 
from the positive control, inactivated vaccinated, or live-attenuated vaccinated dams, respectively. The PCV2 antigen in hearts 
was only detectable in the positive control litter (23% of the fetuses). The PCV1-2 DNA was detected in 29% of the fetuses in the 
litter from the 1-LIVE-VAC-PCV2 dam. Under the conditions of this pilot study, both vaccines protected against PCV2 viremia 
in breeding age animals; however, vertical transmission was not prevented.
Résumé
L’objectif de cette étude pilote était de déterminer l’efficacité de vaccins inactivés (1 ou 2 doses) et vivants atténués chimériques du circovirus 
porcin (PCV)1-2 chez des truies en utilisant le modèle de semence inoculée avec PCV2. Trente-cinq truies ont été réparties de manière aléatoire 
en six groupes : témoins négatif et positif, 1 dose de vaccin PCV1-2 inactivé et challengé (1-VAC-PCV2), 2 doses de vaccin PCV1-2 inactivé 
et challengé (2-VAC-PCV2), 1 dose de vaccin PCV1-2 vivant atténué non-challengé (1-LIVE-VAC), et 1 dose de vaccin PCV1-2 vivant 
atténué et challengé (1-LIVE-VAC-PCV2). Le vaccin PCV1-2 inactivé a induit des niveaux plus élevés d’anticorps anti-PCV2 spécifiques 
chez les truies. Toutes les stratégies de vaccination ont entrainé une bonne protection contre une virémie par PCV2 chez les truies, alors 
que la majorité des truies non-vaccinées étaient virémiques. Quatre des 35 truies sont devenues gestantes : une truie témoin négatif, une 
truie témoin positif, une truie 2-VAC-PCV2, et une truie 1-LIVE-VAC-PCV2. L’ADN du PCV2 a été détecté chez, respectivement, 100 %, 
67 %, et 29 % des fœtus obtenus des truies témoin positif, vaccin inactivé ou vaccin vivant atténué. L’antigène PCV2 dans le cœur n’était 
détectable que dans les portées des témoins positifs (23 % des fœtus). L’ADN de PCV1-2 a été détecté chez 29 % des fœtus dans la portée 
d’une truie 1-LIVE-VAC-PCV2. Dans les conditions de cette étude pilote, les deux vaccins étaient protecteurs contre une virémie par PCV2 
chez des animaux en âge de se reproduire; toutefois ils n’empêchaient pas la transmission verticale.
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Porcine circovirus type 1 was first identified as a contaminate of 
a continuous porcine kidney cell line (PK-15) in 1974 (4,5). Despite 
being widespread in the pig population, PCV1 has been shown 
to be non-pathogenic in pigs (6,7). However, PCV2 is associated 
with a group of diseases collectively called PCV-associated disease 
(PCVAD), including PCV2-associated reproductive failure in mature 
animals (8).
Porcine circovirus type 2-associated reproductive failure is typically 
characterized by increased numbers of abortions, mummified and 
stillborn fetuses, and weakborn piglets (9). Confirmation of PCV2 as 
the causative agent of reproductive failure is done by identification of 
myocardial fibrosis, lymphoplasmacytic myocarditis, and association 
of PCV2 antigen with the fetal heart lesions by immuno histochemistry 
(IHC) (10). Newborn piglet serum or fetal thoracic fluid may also be 
positive for PCV2 DNA or PCV2-specific antibodies (10).
It has been shown that a chimeric PCV1-2 strain with the capsid 
gene of PCV2 in the backbone of the non-pathogenic PCV1 was 
non-pathogenic under experimental conditions. The inactivated com-
mercial PCV2 vaccine “FosteraTM PCV” was recently reintroduced 
to the global market and is based on the PCV1-2 chimera. The non-
pathogenic chimeric PCV1-2 virus may also have potential for use 
as a live-attenuated chimeric PCV2 vaccine (11,12).
Porcine circovirus type 2 can be further divided into at least 3 sub-
types. The most important subtypes are prevalent worldwide and 
include PCV2a, which was the predominant strain in the pig popula-
tion before the year 2000; and PCV2b, which has replaced PCV2a in 
most herds and is currently the predominant PCV2 genotype in North 
America (13,14). One of the main differences between PCV2a and 
PCV2b is in the signature motif in ORF2. Comparative pathogenicity 
studies among the 2 PCV2 subtypes side by side in experimentally 
infected pigs have failed to show any differences in virulence (15,16).
Vaccination against PCV2 has been shown to be highly effective 
in decreasing losses associated with PCVAD. There are currently 
several types of commercial vaccines available including an inac-
tivated PCV2 vaccine for use in dams or piglets (Circovac; Merial, 
Lyon, France), 2 subunit vaccines based on PCV2-ORF2 expressed 
in baculovirus for use in growing pigs (Circumvent PCV; Merck 
Animal Health Summit, New Jersey, USA and Ingelvac CircoFLEX; 
Boehringer Ingelheim, Vetmedica, Ingelheim, Germany), and an 
inactivated chimeric PCV1-2 vaccine for use in growing pigs (Fostera 
PCV; Zoetis, Florham Park, New Jersey USA, formerly Suvaxyn 
PCV2 One Dose; Fort Dodge Animal Health, Fort Dodge, Iowa, 
USA). All these vaccines are based on PCV2a with differences in 
dosage and recommended timing for use of these products (8).
All commercially available PCV2 vaccines are inactivated or sub-
unit vaccines. Another type of vaccine currently in the experimental 
stage of development is a live-attenuated PCV2 vaccine based on 
a chimeric PCV1-2. One concern with any live-attenuated vaccine 
is the development of vaccine virus viremia in immunized pigs 
and spread of the vaccine virus among pigs and herds. It has been 
previously shown that a live-attenuated chimeric PCV1-2 vaccine 
prevented viremia and decreased macroscopic and microscopic 
lesions caused by PCV2 infection (12). Interestingly, a chimeric 
PCV1-2 was recovered from clinically healthy pigs on Canadian 
farms with no signs of PCVAD (17). Another concern with a live-
attenuated chimeric vaccine based on the PCV1 backbone is the 
disease causing potential of PCV1. It has been previously shown that 
PCV1 is associated with congenital tremors in newborn fetuses (18), 
but other authors failed to reproduce these initial findings (19,20). 
Recently, PCV1 has been associated with hemorrhages in lung tissues 
of fetuses experimentally inoculated with the PK-15 cell-derived 
PCV1 isolate but not a field isolate of PCV1 (21).
Porcine circovirus type 2 is shed in oral, nasal, and fecal excre-
tions (22–24), and has been found in boar semen without damaging 
sperm morphology (25). It has also been shown that insemination 
of naïve dams with semen containing low levels of PCV2 DNA did 
not result in virus transmission (viremia, seroconversion) or repro-
ductive failure (26); however, insemination with semen spiked with 
high levels of PCV2 was capable of inducing reproductive failure 
in naïve dams (10).
The objective of this pilot study was to determine efficacy of a 
commercial inactivated (administered as 1 or 2 dose) vaccine and 
an experimental live-attenuated chimeric PCV1-2 vaccine to prevent 
viremia in sows using the PCV2-spiked semen model. Four of the 
35 sows became pregnant, including 2 vaccinated sows (2 dose 
inactivated and 1 dose live-attenuated PCV1-2 vaccine), a negative 
control and a positive control sow, and their litters were utilized to 
further determine the efficacy of sow vaccination in preventing or 
reducing vertical transmission.
M a t e r i a l s  a n d  m e t h o d s
Animals and housing
Thirty-five dams, ranging in age from 792 to 2389 d (Table I) 
and in parity from 1 to 7, were obtained from a herd confirmed to 
be free of PCV2 by serology and polymerase chain reaction (PCR) 
testing. The dams were transported over a 3-day interval approxi-
mately 250 km to Iowa State University in Ames, Iowa, and housed 
in groups of 1 to 6 in a total of 17 rooms depending on room size. 
Each room was equipped with one nipple drinker and sows were 
fed daily with a pelleted feed ration, which contained whey, but 
was free of other animal proteins and antibiotics (Nature’s Made; 
Heartland Co-op, Cambridge, Iowa, USA). Fifteen of the 35 dams 
were pregnant on arrival (between 15 to 116 d of gestation) and the 
pregnancies were terminated in all dams less than 52 d into gesta-
tion by using 2 mL cloprostenol sodium (Estrumate; Merck Animal 
Health, Summit, New Jersey, USA).
Experimental design
The experimental protocol was approved by the Iowa State 
University Institutional Animal Care and Use Committee. The exper-
imental design is summarized in Table I. After arrival, the dams were 
blocked by age and randomly assigned to groups and rooms. After 
an acclimation period of approximately 3 mo, 12 of the 35 dams were 
vaccinated with one 2 mL dose of an experimental live-attenuated 
chimeric PCV1-2 vaccine (1-LIVE-VAC, and 1-LIVE-VAC-PCV2), 
6 of the 35 dams were vaccinated with one 2 mL dose of an inac-
tivated chimeric PCV1-2 vaccine (1-VAC-PCV2), 6/35 dams were 
vaccinated with 2 doses of an inactivated chimeric PCV1-2 vaccine, 
1 mL, 3 wk apart (2-VAC-PCV2), and 11 of the 35 dams remained 
unvaccinated as controls. Estrus cycles were synchronized for all 
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dams as  previously described (10), followed by artificial insemina-
tion 35 d post one dose inactivated chimeric or live vaccination or 
14 d post 2 dose inactivated chimeric vaccination. Extended semen 
obtained from 9 boars all of the same breed and confirmed to be 
PCV2 negative was used for artificial insemination. Each dam in the 
negative control group and in the 1-LIVE-VAC group received 80 mL 
of PCV2-free semen. All dams in the other groups were inseminated 
with 75 mL of semen spiked with 5 mL of PCV2b immediately before 
insemination. Inseminations were repeated in 24 h intervals for 3 d. 
Dams were monitored for signs of estrus, and if any recycled they 
were  re-inseminated using 80 mL PCV2-free semen in 24 h intervals 
for 3 d. After vaccination, the dams were bled weekly until necropsy 
at 105 d post inoculation (DPI). All dams tested negative for specific 
antibodies against porcine reproductive and respiratory syndrome 
virus and porcine parvovirus prior to initiation of the study and at 
termination of the study (data not shown). At necropsy all fetuses 
were removed from the uterus, euthanized, and samples were 
collected.
Vaccination
Dams in the 1-VAC-PCV2 group were vaccinated with 2 mL of 
PCV2 vaccine (Suvaxyn PCV2; Fort Dodge Animal Health Inc. Fort 
Dodge, Iowa, USA; now known as Fostera PCV; Zoetis, Florham 
Park, New Jersey, USA), dams in the 2-VAC-PCV2 group were vac-
cinated with 2 doses (Suvaxyn PCV2), 1 mL, 3 wk apart, and dams 
in the 1-LIVE-VAC and 1-LIVE-VAC-PCV2 groups were vaccinated 
with one 2 mL dose of an experimental live-attenuated chimeric 
PCV1-2 vaccine at a dose of 104 median tissue culture infective dose 
(TCID50), as previously described (27).
Clinical observation
All dams were examined daily for signs of illness such as lethargy, 
respiratory disease, inappetence, and lameness, as well as signs of 
return to estrus.
Inoculation
The PCV2b isolate NC-16845 (16) used for the inoculation 
was propagated in PCV1-free PK-15 cells to an infectious titer of 
104.5 TCID50. Five weeks after vaccination of the one dose groups and 
2 wk after booster vaccination of the 2 dose group, 24 of the 35 dams 
(1-VAC-PCV2; 2-VAC-PCV2, 1-LIVE-VAC-PCV2, positive controls) 
were artificially inseminated with semen spiked with 5 mL PCV2b.
Sample collection
Blood was collected from dams in 8.5 mL serum separator tubes 
(BD vacutainer; BD Biosciences; San Jose, California, USA) on a 
weekly basis from the time of vaccination until necropsy at 105 DPI 
(except on 63 DPI). At necropsy, fetal blood was collected from all 
live fetuses and fetal thoracic fluid was collected from all dead 
or mummified fetuses. If no serum or fetal thoracic fluid could 
be obtained from a fetus, tissue homogenates were collected. The 
blood was centrifuged at 3220 3 g for 10 min at 4°C and the serum 
was aliquoted into 5 mL polystyrene round bottom tubes (Thermo 
Fisher Scientific, Hampton, New Hampshire, USA) and stored at 
220°C until testing.
Serology
All serum samples were tested for PCV2-specific IgG antibodies 
using an indirect PCV2 ORF2-based enzyme-linked immunosor-
bent assay (ELISA), as previously described (28). The results were 
expressed as sample-to-positive (S/P) ratio. Samples were consid-
ered to be negative if the S/P ratio was , 0.2 and positive if the 
S/P ratio was $ 0.2. In addition, all serum samples from dams at 
DPI 0 were tested for PCV2-specific neutralizing antibodies using 
a fluorescence focus neutralization (FFN) assay (29). Virus neutral-
izing titers are expressed as the highest serum dilution resulting in 
a 90% reduction in virus replication compared to the virus control.
Porcine circovirus type 2 DNA detection
The PCV2 viral DNA was extracted from the serum samples, 
fetal thoracic fluid samples, or tissue homogenates using a viral 
isolation kit (MagMax Viral Isolation Kit; Applied Biosystems, 
Carlsbad, California, USA) on an automated magnetic particle pro-
cessor (KingFisher Flex System; ThermoFisher Scientific, Pittsburgh, 
Pennsylvania, USA). The PCV2 DNA detection, to verify and 
quantify the presence of PCV2 in all samples, was done using a 
quantitative real-time PCR (TaqMan Fast Universal PCR Master Mix; 
Applied Biosystems) using the same primers and probe at the same 
concentrations, as previously described (30). The total PCR reaction 
volume, including 2.5 μL of DNA extract, was 25 μL. The thermal 
Table I. Experimental design
    PCV2
  Mean age in days  vaccine PCV2 
Group Animals (95% CI) 35* 14* inoculation
Positive control 6 1174 (1421; 928) — — Spiked semen
2-VAC-PCV2a 6 1247 (1654; 841) YES YES Spiked semen
1-VAC-PCV2a 6 1291 (1836; 746) YES — Spiked semen
1-LIVE-VAC-PCV2b 6 1462 (1991; 935) YES — Spiked semen
1-LIVE-VACb 6 1363 (1719; 1008) YES — —
Negative control 5 1048 (1290; 806) — — —
a Dams vaccinated with a commercial vaccine (Suvaxyn PCV).
b Dams vaccinated with an experimental live-attenuated chimeric PCV1-2 vaccine.
* — days before insemination or PCV2 infection; PCV — porcine circovirus; CI — confidence 
 interval.
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cycle conditions were 95°C for 2 min, followed by 40 cycles of 95°C 
for 10 s and 60°C for 1 min. The sensitivity of the PCV2 real-time 
PCR was 1 3 103 copies/mL (2.5 copies per reaction). Samples were 
considered negative if no signal was observed during the 40 ampli-
fication cycles.
The PCV1-2 PCR
The PCV1-2 DNA detection was done to verify the presence of 
any PCV1-2 using the same DNA extracts as for the PCV2 PCR. The 
DNA quantification was done using quantitative real-time PCR 
(TaqMan Universal PCR Master Mix; Applied Biosystems) with the 
same primers and probes at the same concentrations, as previously 
described (27). The total PCR reaction volume was 25 mL. The ther-
mal cycle conditions were 50°C for 2 min, 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 s, 55°C for 30 s, and 60°C for 1 min. The 
sensitivity of the PCV1-2a real-time PCR was 8.13 3 104 copies/mL 
(204 copies per reaction). Samples were considered negative if no 
signal was observed during the 40 amplification cycles.
Necropsy
All dams were humanely euthanized by intravenous pentobarbital 
sodium overdose (Fatal Plus; Vortech Pharmaceuticals, Dearborn, 
Michigan, USA) and necropsied at 105 DPI. The extent of total mac-
roscopic lung lesions (ranging from 0% to 100%) was scored by a vet-
erinary pathologist in a blinded fashion, as previously described (31). 
Fetuses were surgically removed from the uterus immediately after 
euthanasia of the dam. Fetal blood was collected from all live fetuses, 
and the piglets were then humanely euthanized by intravenous pento-
barbital sodium overdose (Vortech Pharmaceuticals) and necropsied. 
If blood collection was not possible (mummified or dead fetuses), fetal 
thoracic fluid was collected if available. Fetal heart tissues were col-
lected at necropsy, a section stored fresh at 220°C until further testing 
and a section fixed in 10% neutral buffered formalin and then routinely 
processed for histological examination, as previously described (10).
Immunohistochemistry (IHC)
Immunohistochemistry for detection of PCV2-specific antigen was 
done on fetal hearts using a rabbit polyclonal antiserum (32). Antigen 
scoring was done by a veterinary pathologist blinded to treatment 
groups and the scores were reported from 0 (no antigen detected) to 
3 (abundant PCV2 antigen), as previously described (33).
Statistical analysis
Statistical analysis of the data was done using computer soft-
ware (SAS and JMP softwares, version 9.0.0; SAS Institute, Cary, 
North Carolina, USA). Summary statistics were calculated for all 
groups to assess the overall quality of the data, including normal-
ity. Real-time PCR results and FFN results were log10 transformed 
prior to statistical analysis. Continuous repeated measured data 
(PCV2 viremia, ELISA S/P ratios) were assessed using the repeated 
measures analysis of variance (ANOVA) method. In each repeated 
measures ANOVA analysis, group, time, and their interaction were 
fixed effects whereas animal was the subject of repeated measures. 
Differences in response among groups were assessed using F-tests by 
time. Non-repeated measurements (FFN results) were assessed using 
one-way ANOVA. If an ANOVA F-test was significant (P , 0.05), 
then pairwise t-tests with the Tukey’s adjustment were used to assess 
specific group differences.
Figure 1. Mean group PCV2 ELISA sample-to-positive (S/P) ratios (6 standard error) in serum at different 
days post inoculation. Negative values are included in the group means. An S/P ratio $ 0.2 was consid-
ered positive. Groups with different letters (A,B,C) on a certain day post inoculation have significantly 
(P , 0.05) different group S/P ratios.
M
ea
n 
gr
ou
p 
S/
P
 r
at
io
s
Days post inoculation
12 The Canadian Journal of Veterinary Research 2000;64:0–00
Re s u l t s
Clinical observation
One 1-LIVE-VAC-PCV2 dam and one negative control dam devel-
oped severe lameness and were humanely euthanized at 84 DPI. 
The overall conception rate of the sows was 11.4% (4/35 sows) after 
insemination during the first estrus cycle following synchroniza-
tion and 37.1% (13/35) after 16 sows were rebred during subse-
quent estrus cycles. Among all pregnant animals (first or second 
cycle of insemination), none displayed recognizable signs of early 
abortions.
Reproductive measures
Of the 4 sows that were pregnant after initial insemination 
using PCV2-spiked semen, the litter compositions were as follows: 
1 mummified and 12 live fetuses (positive control dam), 4 mummi-
fied and 11 live fetuses (2-VAC-PCV2), 2 mummified and 12 live 
fetuses (1-LIVE-VAC-PCV2), and 0 mummified and 10 live fetuses 
(negative control dam). Fetuses that were not full-term at necropsy 
(pregnant upon second insemination after returning to estrus) were 
excluded from analysis. The litter distribution of these dams was as 
follows: 27 fetuses (positive control dams, n = 2), 18 fetuses (2-VAC-
PCV2 dams, n = 2), 37 fetuses (1-VAC-PCV2 dams, n = 3), 17 fetuses 
(1-LIVE-VAC-PCV2 dams, n = 1), and 10 fetuses (1-LIVE-VAC dam, 
n = 1). Viability data at the time of extraction from the uterus was 
not obtained.
Seroconversion to PCV2
Negative control dams remained negative for PCV2-specific anti-
bodies throughout the study (Figure 1; Table II). All 1-VAC-PCV2 
and 2-VAC-PCV2 dams had seroconverted to PCV2 prior to the first 
blood collection at 27 DPI (Table II). Five of the 6 1-LIVE-VAC and 
5 of the 6 1-LIVE-VAC-PCV2 dams had seroconverted by DPI 7, 
respectively. There was a significant group by time interaction 
(P , 0.001). There was no significant difference in antibody levels 
between the 1-VAC-PCV2 and 2-VAC-PCV2 groups at any time 
points, except at 27 DPI (Figure 1). Also, there was no significant 
difference in antibody levels at any time points between the 1-LIVE-
VAC and 1-LIVE-VAC-PCV2 groups (Figure 1). Dams vaccinated 
with the inactivated vaccine had significantly higher (P , 0.05) S/P 
ratios as detected by ELISA, compared to those vaccinated with the 
live-attenuated vaccine at every DPI throughout the course of the 
study. Positive controls had similar S/P ratios as the LIVE-VAC and 
1-LIVE-VAC-PCV2 groups from 28 DPI through 105 DPI (Figure 1). 
All 45 live fetuses from all 4 litters were negative for PCV2-specific 
antibodies at derivation (data not shown).
Neutralizing antibodies
On the day of challenge, the log10 transformed FFN titers were 
2.71 6 0.08 units for 1-VAC-PCV2, 2.96 6 0.24 units for 2-VAC-PCV2, 
1.57 6 0.17 units for 1-LIVE-VAC, 1.52 6 0.13 units for 1-LIVE-
VAC-PCV2, 0.28 6 0.17 units for the negative control group, and 
0.28 6 0.18 units for the positive control group. The inactivated 
chimeric PCV1-2 vaccine induced significantly higher (P , 0.05) 
levels of neutralizing antibodies compared to the live-attenuated 
vaccine prior to challenge.
The PCV2 viremia
Negative control dams, as well as the 1-LIVE-VAC dams, remained 
negative for PCV2 viremia throughout the study (Table III). There 
was a significant group by time interaction (P , 0.001). Specifically, 
positive control dams developed PCV2 viremia by 14 DPI and had 
significantly higher (P , 0.05) levels of viremia from 14 DPI through 
56 DPI compared with vaccinated groups (Figure 2). Challenged, 
vaccinated dams had detectable PCV2 DNA at varying DPI dur-
ing the study (Table III) without significant differences among the 
vaccinated groups at any time point (Figure 2). Of the 4 dams that 
became pregnant after initial insemination, the positive control dam 
was viremic from 14 through 49 DPI, the 2-VAC-PCV2 sow was not 
viremic, the 1-LIVE-VAC-PCV2 sow was viremic at 105 DPI, and 
PCV2 viremia was not detected in the negative control dam. The 
prevalence and concentration of PCV2 DNA detected in the fetuses 
obtained after initial insemination are summarized in Table IV. Due 
to the length of time after inoculation of the dam with PCV2, PCV2 
DNA detection was not attempted on the fetuses resulting from the 
second insemination.
The PCV1-2 viremia
All dams remained negative for PCV1-2 DNA throughout the 
course of the study. Three of 14 fetuses from the 1-LIVE-VAC-PCV2 
litter were positive for PCV1-2 DNA with an average log10 trans-
formed mean amount PCV1-2 DNA of 6.45 6 0.31 per mL. All other 
piglets were negative for PCV1-2 DNA (data not shown).
Table II. Group prevalence of porcine circovirus type 2 (PCV2)-specific antibodies in serum. Groups that contain seropositive 
pigs are shaded in grey. Vaccines were administered at 235 DPI and in the case of the 2 dose product a second dose was given 
at 214 DPI. Dams were challenged at 0 days post inoculation with PCV2 free or PCV2 spiked semen
 DPI
Group 27 0 7 14 21 28 35 42 49 56 77 84 91 98 105
Positive controls 0/6 0/6 0/6 0/6 0/6 4/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
2-VAC-PCV2 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
1-VAC-PCV2 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
1-LIVE-VAC-PCV2 2/6 4/6 5/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 5/5a 5/5a 5/5a
1-LIVE-VAC 1/6 3/6 5/6 5/6 5/6 5/6 5/6 5/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
Negative controls 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/4a 0/4a 0/4a
a One negative control dam and a 1-LIVE-VAC-PCV2 dam developed severe lameness and were euthanized at DPI 84.
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Macroscopic lesions
Lungs, lymph nodes, and the reproductive tract of the dams were 
examined for gross lesions and all were macroscopically normal.
Immunohistochemistry
All 10 piglets from the negative control dam and all 29 piglets 
from the 2-VAC-PCV2 and 1-LIVE-VAC-PCV2 dams were negative 
for PCV2 antigen in heart tissues. Low-to-abundant amounts of 
PCV2 antigen were detected in the hearts of 3 of 13 fetuses from the 
positive control dam.
D i s c u s s i o n
Evidence from the field supports an association of PCV2 with 
reproductive failure. Although limited experimental trials have been 
conducted in breeding age animals, it has been previously demon-
strated that dams develop PCV2 viremia when inseminated with 
PCV2-positive semen (10). In this pilot study, sows were inseminated 
with PCV2-spiked semen and viremia was detected in the positive 
control group further confirming that PCV2 is infectious when 
administered via artificial insemination. The limited information 
available in the literature on the efficacy of inactivated PCV2 vac-
cines in breeding age animals indicates that PCV2-vaccinated dams 
may deliver PCV2 positive piglets (34), potentially an important 
source of PCV2 transmission in pig production systems.
Currently there are 3 commercial vaccines on the market approved 
for use in healthy pigs (3 wk of age or older), and one vaccine 
is approved for use in both dams and growing pigs. All of these 
commercial vaccines are inactivated. Experimental and field trial 
evidence clearly demonstrates that use of these vaccines reduces 
losses associated with PCVAD in growing pigs (35,36). In this study, 
an experimental attenuated live PCV1-2 vaccine was utilized for the 
Table III. Group prevalence of porcine circovirus type 2 (PCV2) DNA in serum. Groups that contain viremic pigs are shaded in 
grey. Vaccines were administered at 235 DPI and in the case of the 2 dose product a second dose was given at 214 DPI. Dams 
were challenged at 0 DPI with PCV2 free or PCV2 spiked semen
 DPI
Group 0 7 14 21 28 35 42 49 56 77 84 91 98 105
Positive controls 0/6 0/6 6/6 6/6 6/6 6/6 5/6 5/6 4/6 3/6 1/6 1/6 3/6 3/6
2-VAC-PCV2 0/6 0/6 0/6 1/6 0/6 0/6 0/6 1/6 0/6 1/6 0/6 0/6 1/6 0/6
1-VAC-PCV2 0/6 0/6 0/6 1/6 0/6 1/6 0/6 1/6 0/6 0/6 0/6 1/6 0/6 0/6
1-LIVE-VAC-PCV2 0/6 0/6 1/6 1/6 1/6 0/6 0/6 0/6 0/6 0/6 0/6 0/5a 0/5a 0/5a
1-LIVE-VAC 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6
Negative controls 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/4a 0/4a 0/4a
a One negative control dam and a 1-LIVE-VAC-PCV2 dam developed severe lameness and were euthanized at 84 DPI.
Figure 2. Mean group amount of log10 PCV2 DNA (6 standard error) in serum at different days post 
inoculation. Negative values are included in the group means. A sample with no threshold cycle (CT) value 
during the 40 amplification cycles was considered negative. An “A” next to the positive control group on a 
certain day post inoculation indicates significantly (P , 0.05) different group log10 PCV2 DNA compared 
to the PCV2 challenged, vaccinated groups (1-LIVE-VAC-PCV2, 1-VAC-PCV2, 2-VAC-PCV2).
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first time in breeding age animals, and compared to 2 different dose 
regimens of the inactivated version of the vaccine. The results indi-
cate that the use of the 3 different vaccination protocols all decreased 
PCV2 viremia and increased anti-PCV2-specific antibody production 
in dams when compared to the positive control group.
The exact mechanism for the decrease of PCV2 viremia in vacci-
nated animals is unknown, but likely due to development of a com-
bination of cellular and humoral immune responses. Interestingly, 
the groups vaccinated with the inactivated chimeric PCV1-2 vaccine 
(1-VAC-PCV2 and 2-VAC-PCV2) developed detectable PCV2-specific 
antibody levels earlier and maintained higher levels throughout the 
study compared to those vaccinated with the live-attenuated chime-
ric vaccine (1-LIVE-VAC and 1-LIVE-VAC-PCV2). In contrast to these 
results in breeding age animals, a previous study comparing several 
commercial and experimental vaccines in young pigs found no 
significant differences between any of the commercial vaccines (27).
In Canada, PCV1-2 was recently isolated from 3 different pigs in 
3 different herds vaccinated with a commercial PCV2 vaccine based 
on an inactivated chimeric PCV1-2 (17). Several studies have shown 
that the PCV1-2 infectious DNA clones and the live-attenuated 
PCV1-2 vaccine are capable of inducing an antibody response, but 
are attenuated in pigs and not capable of producing any characteris-
tic lesions of PCV2 infection (11,12,37). In this study, the 1-LIVE-VAC 
dams showed no evidence of PCV2 or PCV1-2 viremia; however, 
they did develop a PCV2-specific antibody response. The 1-LIVE-
VAC-PCV2 dams developed PCV2 viremia at selected time points at 
low levels, which quickly resolved. As the sensitivity of the PCV1-2 
PCR assay was low, it is possible that PCV1-2 DNA was present 
but at too low a level to be detected. Overall, the results are simi-
lar to previous studies in which some PCV1-2 vaccinated animals 
developed viremia, while others did not; however, as in this study, 
the majority of the animals seroconverted and had no or minimal 
lesions characteristic of PCV2 infection (12,37). These results further 
confirm that the live PCV1-2 chimeric vaccine is capable of inducing 
a humoral immune response and remains attenuated.
In this study, only 11.4% (4/35) of the sows became pregnant 
during the first artificial insemination and only 37.1% (13/35) sows 
became pregnant overall. Low reproductive rates are not uncom-
mon in older parity sows. In addition, PCV2 has been implicated in 
early embryonic death (38) and re-absorption leading to irregular or 
regular return to estrus. Several sows arrived at the research facility 
with varying stages of pregnancy, which were purposely terminated, 
potentially causing complications in their ability to conceive during 
the subsequent artificial insemination attempts. However, previ-
ously, using the same insemination technique and PCV2 dose but a 
different sow source, conception rates of 88.9% (8/9) (39) and 66.7% 
(6/9) (10) were observed. Among all pregnant animals (first or sec-
ond cycle of insemination) none displayed signs of early abortions 
under the study conditions.
Among the animals that became pregnant during the first cycle, 
PCV2-positive piglets were detected in all 3 challenged sows regard-
less of vaccination status, further confirming that dam vaccination 
does not prevent vertical PCV2 transmission. The exact mechanism 
of how and when fetuses became infected with PCV2 remains 
unknown. Possibilities include (I) directly via the semen at the time 
of fertilization, (II) localized intrauterine infection via the semen and 
spread to fetuses at any time during gestation, or (III) re-circulating 
PCV2 from the blood of the dam and cross-placental infection at 
any time during gestation. In this study, PCV2 viremia was detected 
in the positive control dam from 14 through 49 DPI, but not in any 
of the other 2 challenged dams. All dams were tested for presence 
of PCV2 viremia once a week. Therefore, a short viremia (less than 
7 d) could have remained undetected under the study conditions. 
The fact that vaccinated dams can still deliver PCV2-positive piglets 
causes some to question the value of vaccination in breeding age 
females; however, while the vaccines did not entirely prevent PCV2 
spread to fetuses in the current study, vaccination did decrease the 
overall PCV2 load in the dam and fetuses.
The vaccination protocols in the pregnant sows (1-LIVE-VAC-
PCV2 and 2-VAC-PCV2) resulted in a decrease in PCV2 DNA detec-
tion in piglets (28.6% and 66.7%, respectively) when compared to the 
positive control group (100%), indicating both types of the PCV1-2 
chimeric vaccine are efficacious in breeding age animals. However, 
due to the low numbers of pregnancies in this study, these results 
should be interpreted with caution. In fetuses, PCV2 antigen detec-
tion was done on fetal heart tissues since PCV2 antigen in fetuses 
was previously shown to be found predominantly in the heart and 
tonsil of piglets (34,39). The PCV2 antigen was only detected in the 
positive control piglets in the current study. This is further confirma-
tion that both vaccines are efficacious in decreasing levels of PCV2.
To further evaluate the safety of the live-attenuated PCV1-2 vac-
cine, all 45 live piglets and 7 mummified fetuses from pregnant sows 
at first insemination cycle (n = 4) were tested for presence of PCV1-2 
DNA. Three of 14 piglets from the 1-LIVE-VAC-PCV2 dam were 
positive for PCV1-2 DNA at birth; however, no lesions were noted 
and no PCV2 antigen was detected in the fetal myocardium. Only 
fetal heart tissues were investigated in the current study; however, 
the tissue tropism of PCV1-2 is unknown. Porcine circovirus type 1 
has been previously identified in fetal lung tissues (21). Therefore, 
PCV1-2, although unlikely, could have been present elsewhere in the 
fetal tissues. As a PCV1-2 chimeric virus was identified in Canadian 
swine herds, the risks of introduction of a live-attenuated PCV2 vac-
cine for use in breeding age females needs to be seriously considered 
before approval.
To our knowledge, this is the first study investigating the use of a 
live PCV2 vaccine in breeding animals. While the pilot data obtained 
indicate that the inactivated chimeric PCV1-2 vaccine was capable 
of inducing higher levels of PCV2-specific antibodies throughout 
Table IV. Mean group amount of log10 porcine circovirus type 2 
(PCV2) DNA (6 standard error) and prevalence in serum or 
fetal thoracic fluid of piglets born to dams vaccinated or 
unvaccinated and infected with PCV2. A sample with no 
threshold cycle (CT) value during the 40 amplification cycles 
was considered negative
Treatment PCV2 DNA Prevalence
Positive control 6.72 6 0.57 13/13
2-VAC-PCV2 3.09 6 0.67 10/15
1-LIVE-VAC-PCV2 1.65 6 0.74  4/14
Negative control 0.00 6 0.00  0/10
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the course of this study when compared to the live-attenuated 
experimental chimeric vaccine, no significant differences among vac-
cinated groups in levels and duration of PCV2 viremia were found. 
All vaccines were capable of reducing viremia in dams. The piglets 
obtained from the 2 vaccinated dams had lower levels of PCV2 in 
comparison to those obtained from the non-vaccinated dam. Live-
vaccine virus viremia was detected in selected dams and piglets at 
low levels of viral load, which was not associated with myocardial 
lesions or antigen.
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